Noxopharm
ASX:NOXSydney, Australia· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileOverview
Australian biotech leveraging Sofra™ and Chroma™ platforms to develop oncology and mRNA‑based immunotherapy candidates.
OncologyImmunologyInflammationAutoimmune
Technology Platform
Sofra™ enhances mRNA vaccine safety and delivers oligonucleotide therapeutics for autoimmune diseases; Chroma™ is an oncology discovery engine generating nucleic‑acid‑based and small‑molecule candidates.
Opportunities
Successful Veyonda® data could unlock oncology partnerships, while Sofra™’s mRNA safety technology may attract collaborations with vaccine manufacturers.
Risk Factors
Heavy reliance on early‑stage clinical results and external financing; competitive pressure from larger firms in mRNA and oncology spaces.
Competitive Landscape
Noxopharm competes with biotech firms developing nucleic‑acid therapeutics and mRNA platforms, differentiating itself through a dual‑platform focus on safety enhancement and oncology discovery.